AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21813728
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy cessation for 1 month or 2 months before the next screening mammogram
Trial: 21813728
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of hormone therapy
Trial: 16444660
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg dose of Melissa officinalis and Valeriana officinalis
Trial: 16444660
Drug: 1800 mg
RxNorm normalized name: glycerin 1800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg dose of Melissa officinalis and Valeriana officinalis
Trial: 16444660
Drug: 600 mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg, 1200 mg, and 1800 mg doses of Melissa officinalis and Valeriana officinalis
Trial: 16444660
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg and 1200 mg doses of Melissa officinalis and Valeriana officinalis
Trial: 14992980
Drug: Galantamine (8,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (8, 16, or 24 mg/day)
Trial: 11789969
Drug: Cilostazol 50
RxNorm normalized name: cilostazol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 50 mg bid
Trial: 24630869
Drug: Vi-rEPA conjugate
RxNorm normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-rEPA conjugate vaccine
Trial: 16490583
Drug: Oral clindamycin
RxNorm normalized name: clindamycin Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clindamycin 300 mg BID
Trial: 16490583
Drug: Oral amoxicillin/clavulanic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin/clavulanic acid 1 g BID
Trial: 10623706
Drug: Temozolomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (200 mg/m²/d for 5 days every 28 days)
Trial: 10623706
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) (250 mg/m²/d for 5 days every 21 days)
Trial: 8250314
Drug: Flumazenil 10
RxNorm normalized name: flumazenil 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 10 mg
Trial: 30972696
Drug: Ticagrelor (0.125-2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (0.125-2.25 mg/kg)
Trial: 25233931
Drug: Nicotine metabolism
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine metabolism by cytochrome P450 2A6‐catalyzed C‐oxidation
Trial: 19668021
Drug: 17 alpha‐hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha‐hydroxyprogesterone caproate (17P) 250 mg weekly injections
Trial: 10440559
Drug: Baseline comparisons
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline comparisons across treatment groups.
Trial: 1983724
Drug: Alprazolam, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam, 1.5 mg/day
Trial: 400194
Drug: Total Body
RxNorm normalized name: Total Body Massager Item
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Body Irradiation (TBI) and Chemotherapy (CVP)
Trial: 400194
Drug: Chemotherapy (CVP)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CVP)
Trial: 400194
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TBI and CVP
Trial: 28124802
Drug: Frequent consumption
RxNorm normalized name: ALLERGENIC EXTRACT,PENICILLIUM FREQUENTANS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequent consumption of Caspian white fish marinated in essential oil of Perilla frutescens (EOPF), 434 g each week or four meals per week.
Trial: 28124802
Drug: Frequent consumption
RxNorm normalized name: ALLERGENIC EXTRACT,PENICILLIUM FREQUENTANS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequent consumption of Caspian white fish without EOPF, 434 g each week or four meals per week.
Trial: 15247553
Drug: Efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 600 mg once daily
Trial: 17065182
Drug: Intensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive intervention at a heart failure clinic by a clinician and a cardiovascular nurse, including 9 scheduled patient contacts over 1 year, comprehensive education, treatment optimisation, and self-care advice.
Trial: 8245671
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g and tinidatsole 500 mg
Trial: 8245671
Drug: Aminoglycoside (netilmycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycoside (netilmycin 150 mg or tobramycin 80 mg) with tinidatsole
Trial: 19210135
Drug: NER uncoated
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NER uncoated 2 x 500 mg
Trial: 19210135
Drug: NER coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NER coated 1 x 1000 mg
Trial: 19210135
Drug: NER coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NER coated 2 x 500 mg
Trial: 19210135
Drug: NER uncoated
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NER uncoated 1 x 1000 mg
Trial: 29794285
Drug: Control (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (usual treatment)
Trial: 15548759
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (alpha‐tocopherol 100 mg/day, beta‐carotene 6 mg/day, vitamin C 100 mg/day, selenium 50 microg/day)
Trial: 8091168
Drug: OME/AMOX (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OME/AMOX (oral OME 40 mg bid and AMOX solute 750 mg tid for 10 days)
Trial: 8091168
Drug: OME (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OME (20 mg per day for 20 days)
Trial: 30013785
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate (375–3000 mg/day)
Trial: 30013785
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (non-iron-based phosphate binders)
Trial: 24101048
Drug: Dose-intensive temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose-intensive temozolomide
Trial: 21816628
Drug: Glenohumeral (GH)
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glenohumeral (GH) steroid injection
Trial: 21816628
Drug: Subacromial (SA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial (SA) steroid injection
Trial: 15560690
Drug: Garlic enteric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic enteric coated tablets for 3 months
Trial: 11422249
Drug: amoxycillin‐clavulanate (13.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxycillin‐clavulanate (13.3 mg/kg 3 times daily)
Trial: 11422249
Drug: cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cefuroxime axetil (15 mg/kg twice daily)
Trial: 9430448
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ID, 5 mg, orally)
Trial: 8018953
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) treatment for less than 2 weeks
Trial: 8018953
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) treatment for 2 weeks or more
Trial: 8018953
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) treatment
Trial: 8018953
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) and N-desmethyltamoxifen (DMT) treatment
Trial: 8018953
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) and N-desmethyltamoxifen (DMT) treatment after 2 weeks
Trial: 3144446
Drug: Fluoride tablet
RxNorm normalized name: Sodium Fluoride Tablets
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride tablet programme (daily administration)
Trial: 3144446
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no fluoride tablets)
Trial: 29233783
Drug: 30-minute tDCS
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-minute tDCS combined with 50mg/day of sertraline
Trial: 29233783
Drug: 20-minute tDCS
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-minute tDCS combined with 50mg/day of sertraline
Trial: 17060567
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg once daily (QD)
Trial: 16271726
Drug: Duloxetine 20
RxNorm normalized name: duloxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 20 mg twice daily (BID)
Trial: 12825868
Drug: Prednisolone 50
RxNorm normalized name: prednisolone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 50 mg daily for 2 weeks
Trial: 7045615
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy alone
Trial: 6247521
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy and radiotherapy (including prophylactic brain irradiation in four patients)
Trial: 28356133
Drug: Abdominal massage
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal massage once daily for 6 weeks
Trial: 26240207
Drug: GARDASIL 9
RxNorm normalized name: Gardasil 9
DrugBank: Human papillomavirus type 58 L1 capsid protein antigen (DB10314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GARDASIL 9 (9‐valent human papillomavirus [9vHPV] vaccine) administered concomitantly with MCV4/Tdap
Trial: 26240207
Drug: MCV4/Tdap administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCV4/Tdap administered concomitantly with 9vHPV vaccine
Trial: 26240207
Drug: Tdap administered
RxNorm normalized name: acellular pertussis vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap administered concomitantly with 9vHPV vaccine
Trial: 12637608
Drug: TNX‐901 (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNX‐901 (450 mg)
Trial: 12637608
Drug: TNX‐901 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNX‐901 (300 mg)
Trial: 12637608
Drug: TNX‐901 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNX‐901 (150 mg)
Trial: 10680434
Drug: Itraconazole solution
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole solution 800 mg day‐1
Trial: 10680434
Drug: Itraconazole solution
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole solution 400 mg day‐1 (s/c1200)
Trial: 10680434
Drug: Itraconazole solution
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole solution 400 mg day‐1 with loading dose of 800 mg day‐1 capsules for 7 days
Trial: 10680434
Drug: Itraconazole solution
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole solution 400 mg day‐1
Trial: 10680434
Drug: Itraconazole capsules
RxNorm normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole capsules 400, 600 or 800 mg day‐1
Trial: 8619361
Drug: Iobitridol (250-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iobitridol (250-300 mg)
Trial: 7256696
Drug: Aspirin (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (0.6 g)
Trial: 7256696
Drug: Dipyridamole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (150 mg)
Trial: 31385041
Drug: Enoxaparin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (20 mg, twice daily), started 24-36 hours after surgery and continued until discharge
Trial: 28596236
Drug: hyperinsulinemic hypoglycemia
RxNorm normalized name: Drugs for treatment of hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperinsulinemic hypoglycemia (bolus insulin)
Trial: 28596236
Drug: hyperinsulinemic euglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperinsulinemic euglycemia (bolus insulin and glucose infusion)
Trial: 21114411
Drug: Intraurethral alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraurethral alprostadil 125 to 250 μg daily for 9 months
Trial: 21114411
Drug: Oral sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sildenafil citrate 50 mg daily for 9 months
Trial: 15375810
Drug: Forced-use therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced-use therapy (FUT) - wearing a thick constraint mitten on the sound arm for as many as 6 hours a day
Trial: 11451210
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 10-80 mg
Trial: 11451210
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 2.5-40 mg
Trial: 7532497
Drug: Remantadine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remantadine (1.5 mg/kg body weight, 3 times a day for 3 days)
Trial: 1071671
Drug: Intravenous labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous labetalol (1-5-2-0 mg/kg)
Trial: 1071671
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of propranolol
Trial: 31996613
Drug: Caffeine (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (280 mg)
Trial: 19760283
Drug: Caffeine (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (0 mg, placebo)
Trial: 17138082
Drug: Landiolol 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol 0 mg/kg (placebo)
Trial: 17138082
Drug: Landiolol 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol 0.1 mg/kg
Trial: 17138082
Drug: Landiolol 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol 0.2 mg/kg
Trial: 17138082
Drug: Landiolol 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol 0.3 mg/kg
Trial: 8940230
Drug: Combined PRP‐T/DTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined PRP‐T/DTP vaccine
Trial: 8940230
Drug: DTP vaccine
RxNorm normalized name: DTP Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP vaccine only
Trial: 1416161
Drug: GTN (glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTN (glyceryl trinitrate) infusion at 0.5 micrograms.kg‐1.min‐1
Trial: 1416161
Drug: Stepwise increasing
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepwise increasing infusion of GTN
Trial: 2860284
Drug: Mérieux human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mérieux human diploid-cell-strain vaccine (HDCSV), 0.1 ml intradermally, at eight sites on day 0, at four sites on day 7, and at one site on days 28 and 91
Trial: 2860284
Drug: Semple vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semple vaccine (SV)
Trial: 2860284
Drug: Mérieux human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mérieux human diploid-cell-strain vaccine (HDCSV)
Trial: 19841161
Drug: Lacosamide 200
RxNorm normalized name: lacosamide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide 200 mg bid alone
Trial: 19841161
Drug: Lacosamide 200
RxNorm normalized name: lacosamide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide 200 mg bid with carbamazepine 200 mg bid
Trial: 19841161
Drug: Carbamazepine 200
RxNorm normalized name: carbamazepine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 200 mg bid alone
Trial: 19841161
Drug: Carbamazepine 200
RxNorm normalized name: carbamazepine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 200 mg bid with lacosamide 200 mg bid
Trial: 18543427
Drug: HyperHaes (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HyperHaes (combined hypertonic colloidal solution)
Trial: 8713219
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate capsules, 220 mg three times a day
Trial: 2105070
Drug: Target PaCO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target PaCO2 corrected to patient's rectal temperature (mean 30.1, SD 1.9 degrees C)
Trial: 417372
Drug: d-amphetamine at
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine at three dose levels
Trial: 6805841
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine sulphate
Trial: 30297322
Drug: Single-dose metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose metronidazole (2 g)
Trial: 24644095
Drug: darunavir/cobicistat 800/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/cobicistat 800/150 mg (FDC G003)
Trial: 24644095
Drug: darunavir/cobicistat 800/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/cobicistat 800/150 mg (FDC G004)
Trial: 24644095
Drug: darunavir 800
RxNorm normalized name: darunavir 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir 800 mg and ritonavir 100 mg (single agents)
Trial: 23923010
Drug: Paclitaxel therapy
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel therapy
Trial: 19597418
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (specific programme of exercise therapy twice a day throughout the entire hospitalization phase)
Trial: 17545373
Drug: Intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination at one fifth of a standard dose
Trial: 17545373
Drug: Standard intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intramuscular vaccination
Trial: 16287454
Drug: Sildenafil (25-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25- or 50-mg, titrated to 100-mg)
Trial: 16287454
Drug: Tadalafil (10-mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (10-mg, titrated to 20-mg)
Trial: 216094
Drug: letosteine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: letosteine (50 mg t.i.d.)
Trial: 216094
Drug: S‐carboxy‐methyl‐cysteine (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐carboxy‐methyl‐cysteine (750 mg t.i.d.)
Trial: 27473629
Drug: IV and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV and perineural dexamethasone (1 ml of a 4 mg/ml dexamethasone solution)
Trial: 27473629
Drug: IV dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexamethasone alone (8 mg)
Trial: 21690303
Drug: Drug facts
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug facts format
Trial: 19809205
Drug: Nifedipine controlled
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine controlled release (CR) 25 mg/day
Trial: 17536870
Drug: Bramitob (300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bramitob (300mg nebulized dose)
Trial: 17536870
Drug: Tobi (300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobi (300mg nebulized dose)
Trial: 15297201
Drug: Platinum-based therapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based therapy
Trial: 15297201
Drug: Combination platinum/paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination platinum/paclitaxel therapy
Trial: 8439017
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravenous midazolam
Trial: 31221679
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion threshold (transfuse if hemoglobin<7.5 g/dl)